Last reviewed · How we verify

ATL-962 — Competitive Intelligence Brief

ATL-962 (ATL-962) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucagon receptor antagonist. Area: Diabetes.

phase 2 Glucagon receptor antagonist Glucagon receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

ATL-962 (ATL-962) — Alizyme. ATL-962 is a glucagon receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ATL-962 TARGET ATL-962 Alizyme phase 2 Glucagon receptor antagonist Glucagon receptor
Zegalogue DASIGLUCAGON Zealand Pharma marketed Antihypoglycemic Agent [EPC] Glucagon receptor 2021-01-01
Low-Dose Glucagon Low-Dose Glucagon Steno Diabetes Center Copenhagen marketed Glucagon receptor agonist Glucagon receptor (GCGR)
morphine and glucagon morphine and glucagon National Taiwan University Hospital marketed Opioid analgesic + glucagon (hormone) Mu-opioid receptor (morphine); glucagon receptor (glucagon)
Glucagon 12.5ng/kg/min Glucagon 12.5ng/kg/min Cambridge University Hospitals NHS Foundation Trust marketed Glucagon receptor agonist Glucagon receptor (GCGR)
CJ-30001/CJ-30002 CJ-30001/CJ-30002 HK inno.N Corporation phase 3 Dual GLP-1/GCG receptor agonist GLP-1 receptor, Glucagon receptor
GZR4 Injection GZR4 Injection Gan and Lee Pharmaceuticals, USA phase 3 Glucagon receptor antagonist Glucagon receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucagon receptor antagonist class)

  1. Merck Sharp & Dohme LLC · 2 drugs in this class
  2. Alizyme · 2 drugs in this class
  3. Claes-Göran Östenson · 1 drug in this class
  4. Gan and Lee Pharmaceuticals, USA · 1 drug in this class
  5. GlaxoSmithKline · 1 drug in this class
  6. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
  7. AbbVie (prior sponsor, Abbott) · 1 drug in this class
  8. Novo Nordisk A/S · 1 drug in this class
  9. Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATL-962 — Competitive Intelligence Brief. https://druglandscape.com/ci/atl-962. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: